79T Stock Overview
Develops, manufactures, and markets e-health solutions in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Medimi AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.01 |
| 52 Week Low | SEK 0.0002 |
| Beta | -0.34 |
| 11 Month Change | -66.67% |
| 3 Month Change | -50.00% |
| 1 Year Change | -87.50% |
| 33 Year Change | -99.04% |
| 5 Year Change | n/a |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 79T | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.8% |
| 1Y | -87.5% | -5.0% | 9.1% |
Return vs Industry: 79T underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 79T underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 79T volatility | |
|---|---|
| 79T Average Weekly Movement | 190.8% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 79T's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 79T's weekly volatility has increased from 111% to 191% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 6 | Johan Wiesel | www.medimiab.com |
Medimi AB (publ) develops, manufactures, and markets e-health solutions in Sweden. It offers Medimi Smart, a comprehensive system for medicine handling; and MedimiFlex, an administration system. The company was formerly known as MedicPen AB (publ) and changed its name to Medimi AB (publ) in May 2021.
Medimi AB (publ) Fundamentals Summary
| 79T fundamental statistics | |
|---|---|
| Market cap | €598.13k |
| Earnings (TTM) | -€1.18m |
| Revenue (TTM) | €361.61k |
1.7x
P/S Ratio-0.5x
P/E RatioIs 79T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 79T income statement (TTM) | |
|---|---|
| Revenue | SEK 4.17m |
| Cost of Revenue | SEK 2.47m |
| Gross Profit | SEK 1.70m |
| Other Expenses | SEK 15.34m |
| Earnings | -SEK 13.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 40.75% |
| Net Profit Margin | -326.89% |
| Debt/Equity Ratio | 38.7% |
How did 79T perform over the long term?
See historical performance and comparison